A good vaccine requires not only high-quality ingredients but also high-quality equipment.

Release time:

2018-12-03


Overview:

The Shanghai Luxiangyi centrifuge meets the needs of the vaccine industry, adding an extra layer of confidence to vaccine production.

  Abstract: The biopharmaceutical industry primarily encompasses vaccines, antibodies, and blood serum products. From 2016 to 2017, the share of vaccines within this sector was 7.98% and 9.57%, respectively. This clearly demonstrates that vaccine development is indeed quite substantial! For sustainable and impressive growth, both quality and quantity must improve together—rather than merely focusing on superficial increases in quantity alone!


  According to incomplete statistics, China’s biopharmaceutical market has been growing at an accelerating pace in recent years. However, compared to overseas markets, its scale remains relatively small. Notably, from 2017 to 2022, the growth rate accelerated significantly, with an average annual compound growth rate of 71.9%, reaching 17.9 billion yuan in 2022. The Chinese biosimilar market has experienced particularly rapid growth, primarily driven by the following factors: First, the Chinese biopharmaceutical market is generally expanding due to population aging, the rising prevalence of chronic diseases, and the enhanced R&D and production capabilities of Chinese biosimilar companies. Second, biosimilars offer cost advantages that enable them to reach a broader patient population and increase the likelihood of being included in the national medical insurance reimbursement catalog in the near future. Additionally, in recent years, China has established a regulatory framework for biosimilars and introduced supportive policies aimed at promoting their development, which will soon drive strong sales of many best-selling biologic drugs.


  2018-2022 China Biosimilar Market Size Trend Forecast:

456.jpg

  In today’s society, the internet is developing at a rapid pace. Once major news breaks, the power of public opinion cannot be underestimated—just like the recent fake-vaccine scandal, which has sparked widespread discussion! On the one hand, public opinion has exerted significant influence; on the other hand, the government has promptly and proactively launched a series of measures, enabling the incident to be resolved relatively quickly and gradually fading from public attention online. But does this mean the issue is over? No—it’s not. Beyond the government’s subsequent supervision and inspection, even though public attention has waned, manufacturers that have provided technical and equipment support for vaccine production must take the initiative to further improve their equipment in a self-disciplined and responsible manner, thereby laying a solid foundation for China’s biopharmaceutical industry!


  Shanghai Luxiangyi Centrifuge Instrument Co., Ltd., as a long-established centrifuge manufacturer, has widely adopted its products in the biopharmaceutical industry. As early as 2013, the company had already produced biopharmaceutical centrifuges that meet the requirements of the national GMP standards.


  Shanghai Luxiangyi Centrifuge Instrument Co., Ltd. clearly understands that, in addition to high-quality raw materials, good pharmaceutical products also require superior equipment for their production—these two factors are absolutely indispensable. Therefore, every centrifuge designed and developed by Shanghai Luxiangyi is meticulously crafted to achieve even greater performance!


  Vaccines, like pharmaceuticals, have stringent requirements for raw materials and exacting demands on equipment. During production, in addition to preventing human errors and addressing imperfections in equipment that could lead to cross-contamination and pollution, these are the most fundamental and essential design principles for every biopharmaceutical centrifuge!


  According to reliable sources, Shanghai Luxiangyi Centrifuge Instrument Co., Ltd. had already installed and commissioned eight centrifuges for a major Chinese pharmaceutical company in October 2018, specifically for vaccine production. Thus, it is evident that the Shanghai Luxiangyi centrifuge is a high-quality product that meets current market demands. Centrifuge !